Access Dermatology

Breaking News

• Breaking News List »
• 2010 »
• April »

Latanoprost in the treatment of eyelash alopecia areata

A 2-year, prospective, nonblinded, nonrandomized, controlled study of latanoprost/triamcinolone versus latanoprost was conducted in 54 subjects with eyelash alopecia areata universalis. Control patients (n = 10) received 0.5 mg/cm2 and 1 mg/cm2 triamcinolone on their eyebrows and scalp, respectively. The treatment group (n = 44) also received triamcinolone but also applied latanoprost 0.005% (50 ug/mL) to their eyelid margins nightly. Assessments were made 3-monthly for 2 years. Responses to treatment were assessed as total (80-100% regression); moderate (50-70% regression); slight (1-29% regression) or none. Forty patients completed the trial. Complete, moderate, slight and no regrowth occurred in 17.5, 27.5, 30 and 25% of the treated group, respectively. No patients had cosmetically acceptable regrowth ...